# TELEFLEX INC (TFX) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_99dee78224d83d5bfa41 · retrieved 2026-08-12T06:57:23.283Z

## Overview
Teleflex Incorporated is a global provider of medical technologies offering a diverse portfolio of solutions in anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology.

Teleflex Incorporated completed the sale of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, generating estimated after-tax proceeds of approximately $1.25 billion. The company used a portion of the proceeds to pay off the $700 million Term Loan A-2 associated with its acquisition of Biotronik's Vascular Intervention business. Additionally, Teleflex repurchased 1.9 million shares for $250 million during the second quarter and announced a $250 million accelerated share repurchase program effective August 7, 2026, with remaining net proceeds from the OEM divestiture to be deployed toward additional debt reduction and share repurchases under its $1 billion authorization.

## Terms
- Counterparty: Montagu and Kohlberg · Deal value: $1.50B · Consideration: cash

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0000096943-26-000091): 8-K - TELEFLEX INC — *Teleflex Incorporated is a global provider of medical technologies offering a diverse portfolio of solutions in anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology.* Teleflex Incorporated completed the sale of its OEM business to Montagu and Kohlberg for $1.5 billion in cash, generating estimated after-tax proceeds of approximately $1.25 billion. The company used a portion of the proceeds to pay off the $700 million Term Loan A-2 associated with its acquisition of Biotronik's Vascular Intervention business. Additionally, Teleflex repurchased 1.9 million shares for $250 million during the second quarter and announced a $250 million accelerated share repurchase program effective August 7, 2026, with remaining net proceeds from the OEM divestiture to be deployed toward additional debt reduction and share repurchases under its $1 billion authorization.
  https://www.sec.gov/Archives/edgar/data/96943/0000096943-26-000091.txt

## Citations
- 0000096943-26-000091 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000009694326000091